- Pfizer reported $36.8 billion in 2021 sales for its COVID-19 vaccine, making it the highest-selling pharmaceutical product in a single year. The drugmaker expects to make $32 billion from the vaccine in 2022. Pfizer also said it expects to make $22 billion from its COVID-19 antiviral pill, Paxlovid, in 2022. Paxlovid, which was authorized by the FDA Dec. 22, contributed $76 million to the drugmaker’s U.S. sales in the fourth quarter of 2021.
- Moderna said in November it expects to make between $15 billion and $18 billion from its COVID-19 vaccine in 2021. The drugmaker will report its fourth-quarter earnings Feb. 24.
- Regeneron made $5.8 billion from COVID-19 monoclonal antibodies in 2021.
- Gilead Sciences made $5.5 billion from its COVID-19 therapeutic remdesivir, known by the brand name Veklury.
- Eli Lilly made $2.2 billion from COVID-19 monoclonal antibodies in 2021.
- GlaxoSmithKline made $1.9 billion from COVID-19-related treatments in 2021, most notably its monoclonal antibody sotrovimab.
- Merck made $1 billion from its COVID-19 antiviral pill, molnupiravir, in 2021 and expects to sell an additional $5 billion to $6 billion worth.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
